Skip to main content
MainBoardListed
Anlon Healthcare Limited Logo

Anlon Healthcare Limited IPO

Anlon Healthcare Limited IPO

IPO Date :
Issue Price :
Allotment Date :
Listing Date :
List Price :
Lot Size:
Subscription:
Listed Price: ₹ 92.00 (+1.10%)

Following its successful public offering, Anlon Healthcare Limited's made its market debut on 03-09-2025 and is now actively traded on the NSE, BSEplatform. The IPO mobilized 1,33,00,000 Shares in total capital, including 1,33,00,000 Shares in primary equity infusion.

The offering was structured with a price band of ₹86 to ₹91 and minimum investment lots of 164 shares. Investor participation during the subscription window from 26-08-2025 to 29-08-2025 demonstrated market confidence in the company's prospects.

The allotment process concluded on 01-09-2025, allocating shares to successful bidders. The listing represents the culmination of the IPO process, transitioning the company to publicly traded status with enhanced transparency and governance standards.

Anlon Healthcare IPO Details
Lot(s) Distribution

Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.

IPO Reservation
Anlon Healthcare IPO Key Performance Indicator
Company Financials ( In Crores )

Anlon Healthcare IPO About Company

Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company specializing in the production of pharma intermediates and active pharmaceutical ingredients (APIs). It manufactures high-purity pharmaceutical intermediates used in API production and APIs that are utilized in medicines, nutraceuticals, personal care, and animal health products. The company’s offerings are produced in compliance with Indian and international pharmacopeia standards such as IP, BP, EP, JP, and USP. Along with manufacturing APIs and intermediates to global standards, Anlon Healthcare also provides custom manufacturing for complex chemicals, focusing on exceeding purity standards and minimizing impurities to meet customer-specific requirements. The company has obtained Drug Master File (DMF) approval from regulatory authorities including ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. It has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals. Its portfolio comprises 65 commercialized products, 28 at the pilot stage, and 49 undergoing laboratory testing. To ensure consistent product quality, the company follows rigorous testing and process improvements, supported by four laboratories and a 34-member technical team, which includes 24 science graduates. The company’s product range includes pharmaceutical intermediates such as Cyanoethylbenzoic acid, Ketonitrile, and Methyldesloratadine, which serve as key starting materials or advanced intermediates for API manufacturing. Its APIs are essential components in pharmaceutical products, delivering therapeutic effects and being used in various formulations like tablets, capsules, ointments, and syrups, as well as in nutraceuticals, personal care, and veterinary products. As of January 31, 2025, Anlon Healthcare employed 105 people (excluding trainees) along with 8 contract workers.


Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."


Anlon Healthcare IPO Strength Factors

  1. Experienced Leadership: strong promoters and skilled management driving strategy, innovation, and customer-focused growth
  2. High Market Barriers: strict approval cycles and standards create entry barriers, ensuring demand and limiting competition
  3. Advanced Quality Control: four in-house testing labs ensure rigorous checks, optimized processes, and compliance

Anlon Healthcare IPO Risk Factors

  1. Strict Quality Compliance Risk: not meeting specifications or audits may cause cancellations, claims, or business loss
  2. Customer Dependence: limited client base, loss of a key customer can impact revenue and cash flow
  3. Pharma Industry Reliance: heavy dependence on pharma demand, decline or new alternatives may hurt growth and profitability

Anlon Healthcare IPO Lead Manager(s)

  • Interactive Financial Services Limited

Anlon Healthcare IPO Promoter(s)

  1. Punitkumar R. rasadia
  2. Meet Atulkumar Vachhani
  3. Mamata punitkumar Rasadia

Anlon Healthcare IPO Company Details

Anlon Healthcare Limited
Phone:
address:

Anlon Healthcare IPO Registrar

Kfin Technologies Ltd.
Name:
Phone:

Anlon Healthcare IPO FAQs